Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonate therapy in the oncology setting.

Allan Lipton1

  • 1Penn State University, Milton S. Hershey Medical Center, 500 University Drive, Hershey, Pennsylvania, PA 17033, USA. alipton@psu.edu

Expert Opinion on Emerging Drugs
|December 10, 2003
PubMed
Summary

Intravenous bisphosphonates, like zoledronic acid, effectively reduce skeletal complications in metastatic cancer patients. These therapies also help manage cancer treatment-induced bone loss, improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers.

Breast (Edinburgh, Scotland)·2024
Same author

Beyond October, Beyond Pink: A Year-Round Revelation for Women's Breast Health.

Journal of women's health (2002)·2023
Same author

Oncobiology and treatment of breast cancer in young women.

Cancer metastasis reviews·2022
Same author

Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.

Cellular and molecular life sciences : CMLS·2022
Same author

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.

Journal of bone oncology·2022
Same author

Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics.

Cells·2021

Area of Science:

  • Oncology
  • Pharmacology
  • Orthopedics

Background:

  • Metastatic cancer with bone involvement poses significant risks of skeletal complications.
  • Skeletal complications include pain, fractures, spinal cord compression, and hypercalcemia, often requiring interventions like surgery and radiation.
  • Standard cancer therapies may not prevent these bone-related issues.

Purpose of the Study:

  • To evaluate the role of bisphosphonates in managing skeletal complications of metastatic cancer.
  • To assess the efficacy of zoledronic acid in treating bone metastases.
  • To explore the potential of bisphosphonates in preventing cancer treatment-induced bone loss.

Main Methods:

  • Review of clinical data and regulatory approvals for intravenous bisphosphonates, specifically zoledronic acid.
  • Analysis of zoledronic acid's use in treating bone metastases from various solid tumors, breast cancer, and multiple myeloma.
  • Consideration of bisphosphonates for managing cancer treatment-induced bone loss.

Main Results:

  • Intravenous bisphosphonates reduce the risk of skeletal complications and the need for palliative radiation therapy.
  • Zoledronic acid (4 mg IV infusion) is widely used and considered a standard of care for bone metastases in advanced breast cancer and multiple myeloma.
  • Bisphosphonates may offer benefits in preventing bone loss even before skeletal lesions develop.

Conclusions:

  • Intravenous bisphosphonates are crucial in managing skeletal complications associated with metastatic cancer.
  • Zoledronic acid is a key therapeutic agent for bone metastases and shows promise in addressing cancer treatment-induced bone loss.
  • Ongoing research continues to investigate broader applications of bisphosphonates in oncology.

Related Experiment Videos